Johnson & Johnson Rises to #2 in Ranking of Companies ’ Efforts to Expand Access to Medicines Worldwide

Everyone should have the opportunity to lead a healthy life. This requires that we advance equitable access to healthcare and address some of the world’s most devastating and neglected diseases.We are proud that Johnson & Johnson’s actions to expand access to our medicines and focus on addressing diseases that disproportionately impact people in lower- and middle-income countries has made us the 2nd-ranked company globally in the 2022 Access to Medicine Index.Our industry-leading performance marks an improvement, up from 3rd in 2021, and is the sixth consecutive time we are featured as a top three performer by the Index. This is made possible thanks to an enduring commitment and a focus on providing patients around the world access to our lifesaving medicines.Our high rank is an important validation of our decades-long, deliberate, and focused strategy and a testament to our colleagues and partners around the world who work every day to enable access to our innovative medicines and technologies in almost 100 lower- and middle-income countries.We apply access & pricing principles across our entire pharmaceutical portfolio, planning for access early in the research phase. While our dedicated global public health team applies a lab-to-last-mile approach to fight diseases like tuberculosis, HIV, Ebola, and intestinal worms: innovating across all that we do to develop and deliver much-needed medicines, strengthening health systems and supporting frontline health worker...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news